Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment.
Bianchi G, Czarnecki PG, Ho M, Roccaro AM, Sacco A, Kawano Y, Gullà A, Samur AA, Chen T, Wen K, Tai YT, Moscvin M, Wu X, Camci-Unal G, Da Vià MC, Bolli N, Sewastianik T, Carrasco RD, Ghobrial IM, Anderson KC. Bianchi G, et al. Among authors: ho m. Blood Cancer Discov. 2021 Jul;2(4):338-353. doi: 10.1158/2643-3230.BCD-20-0164. Blood Cancer Discov. 2021. PMID: 34268498 Free PMC article.
The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM).
Ho M, Zanwar S, Kapoor P, Gertz M, Lacy M, Dispenzieri A, Hayman S, Dingli D, Baudi F, Muchtar E, Leung N, Kourelis T, Warsame R, Fonder A, Hwa L, Hobbs M, Kyle R, Rajkumar SV, Kumar S. Ho M, et al. Blood Cancer J. 2021 Sep 22;11(9):158. doi: 10.1038/s41408-021-00548-7. Blood Cancer J. 2021. PMID: 34552051 Free PMC article.
Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma.
Zanwar S, Ho M, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Fonder A, Hobbs M, Hwa Y, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Rajkumar SV, Kumar S. Zanwar S, et al. Among authors: ho m. Leukemia. 2022 Mar;36(3):873-876. doi: 10.1038/s41375-021-01433-9. Epub 2021 Oct 11. Leukemia. 2022. PMID: 34635783 No abstract available.
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance.
Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan A, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Ho M, et al. Blood. 2022 Nov 3;140(18):1997-2000. doi: 10.1182/blood.2022017616. Blood. 2022. PMID: 36096078 Free PMC article.
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis.
Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan A, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Ho M, et al. Am J Hematol. 2023 Jan;98(1):49-55. doi: 10.1002/ajh.26762. Epub 2022 Oct 24. Am J Hematol. 2023. PMID: 36226510 Free PMC article.
The burden of myeloma: novel approaches to disease assessment.
Ho M, Kourelis T. Ho M, et al. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):356-362. doi: 10.1182/hematology.2022000348. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485143 Free PMC article. Review.
4,229 results